Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.

3 Sep 2010

Celldex Therapeutics regains worldwide rights to commercialize rindopepimut therapeutic cancer vaccine

Celldex Therapeutics, Inc. announced today it will regain full worldwide rights to develop and commercialize rindopepimut (CDX-110), effective November 1, 2010.

3 Sep 2010

PDL BioPharma reports revenue guidance of $86 million for 2010 third quarter

PDL BioPharma, Inc. today announced revenue guidance for the third quarter ended September 30, 2010 of approximately $86 million, as compared with actual results of $71.4 million for the third quarter of 2009, a 20 percent year-over-year increase.

2 Sep 2010

Researchers identify novel approach to decrease glioblastoma multiforme recurrence

Researchers from the University of Massachusetts Medical School have identified a novel approach of combining chemotherapy with a targeted therapy to decrease the recurrence of glioblastoma multiforme, the most common and aggressive brain tumor.

25 Aug 2010

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.

18 Aug 2010

Medicare disability recipient dies of brain tumor after having coverage interrupted

Milwaukee Journal Sentinel: "Paula Oertel, whose brain tumor disappeared for nine years while she was on an expensive drug and returned after she temporarily lost her insurance coverage, has died as a result of the tumor spreading through her brain. The interruption of her Medicare coverage of the drug directly contributed to her death, contends her doctor, Mark Malkin, chief of neuro-oncology at Froedtert Hospital.

16 Aug 2010

Scientists discover new signaling pathway to reduce tumour growth in glioblastoma multiforme

Malignant gliomas are the most common subtype of primary brain tumor - and one of the deadliest. Even as doctors make steady progress treating other types of solid tumor cancers, from breast to prostate, the most aggressive form of malignant glioma, called a glioblastoma multiforme or GBM, has steadfastly defied advances in neurosurgery, radiation therapy and various conventional or novel drugs. But an international team of scientists, headed by researchers at the Ludwig Institute for Cancer Research (LICR) at the University of California, San Diego School of Medicine, reports in the August 15 issue of Genes & Development that they have discovered a new signaling pathway between GBM cells - one that, if ultimately blocked or disrupted, could significantly slow or reduce tumor growth and malignancy.

16 Aug 2010

New multidisciplinary approach to glioblastoma multiforme treatment offers extended survival rates

The Hospital Universitario Donostia (at the city of Donostia-San Sebasti-n in the Basque province of Gipuzkoa) has incorporated a new glioblastoma multiforme treatment protocol, which could be the starting point for a more effective treatment of this type of cancer. Doctor Nicol-s Sampr-n, specialist in Neurosurgery at the hospital, has presented his PhD at the University of the Basque Country (UPV/EHU) based on the first results of the new treatment method. The work is entitled Glioblastoma multiforme. Analysis of survival and prognostic factors.

13 Aug 2010

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has received preliminary results from a Phase II clinical trial of GDC-0449 from Roche and Genentech, Curis' collaborator and a member of the Roche Group.

9 Aug 2010

EpiCept second-quarter net loss decreases to $4.9 million

EpiCept Corporation today announced operating and financial results for the three and six months ended June 30, 2010, and provided an update with respect to the Company's key business initiatives.

7 Aug 2010

Bradmer second-quarter net loss decreases to US$161,000

Bradmer Pharmaceuticals Inc. today announced its 2010 second quarter financial results.

7 Aug 2010

Scientists discover single-chain protein to destroy GBM cancer cells

A major breakthrough in how to target and destroy the most malignant and aggressive brain cancer cells has been made by researchers at Wake Forest University Baptist Medical Center.Scientists have identified a way to target and destroy Glioblastoma multiforme (GBM) cells without harming healthy cells.

4 Aug 2010

NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM

Northwest Biotherapeutics, Inc. today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical trials, in which patients with newly diagnosed Glioblastoma multiforme ("GBM"), the most rapid and lethal type of brain cancer, were treated with NWBT's DCVax®-Brain personalized immune therapy.

3 Aug 2010

Particles of iron oxide enhance tumor visibility through MRI

Tiny particles of iron oxide could become tools for simultaneous tumor imaging and treatment, because of their magnetic properties and toxic effects against brain cancer cells. In mice, researchers from Emory University School of Medicine have demonstrated how these particles can deliver antibodies to implanted brain tumors, while enhancing tumor visibility via magnetic resonance imaging (MRI).

3 Aug 2010

New York Times article highlights potential value of early cancer detection technology

Manhattan Scientifics, Inc. said today that a July 20th New York Times article titled "Prone to Error: Earliest Steps to Find Cancer" highlights the potential value of the early cancer detection technology developed by Senior Scientific, LLC and licensed by Manhattan Scientifics. The story focused on widespread problems associated with incorrect diagnosis of breast cancer, and cited one study in which 90,000 women either did not have the disease or their pathologist made an error that resulted in incorrect treatment.

27 Jul 2010

Glioblastomas patients with affected stem cell niche experience progression-free survival

Patients with deadly glioblastomas who received high doses of radiation that hit a portion of the brain that harbors neural stem cells had double the progression-free survival time as patients who had lower doses or no radiation targeting the area, a study from the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center has found.

26 Jul 2010

Reducing calorie intake can restrict growth, spread of brain cancer: Researchers

Researchers at Boston College, MA, have found that reducing calorie intake can restrict the growth and spread of brain cancer. Writing in ASN NEURO, Laura Shelton and colleagues report success with mice suffering from glioblastoma multiforme, the most aggressive and invasive form of primary human brain cancer.

23 Jul 2010

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that a 44-year-old female patient with advanced acute promyelocytic leukemia (APL) achieved molecular complete remission with no evidence of disease in the blood cells and/or bone marrow following treatment with CytRx's oncology drug candidate tamibarotene.

23 Jul 2010

Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma

Archer Biosciences, Inc. announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. The primary objective of this study is to determine the safety, tolerability and maximum tolerated dose (MTD) of TPI-287 in combination with temozolomide (TMZ) in adult patients with metastatic melanoma.

20 Jul 2010

CytRx updates on progress in clinical development of bafetinib in three oncology indications

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.

20 Jul 2010

Glioblastoma News and Research

Further Reading

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

Celldex Therapeutics regains worldwide rights to commercialize rindopepimut therapeutic cancer vaccine

PDL BioPharma reports revenue guidance of $86 million for 2010 third quarter

Researchers identify novel approach to decrease glioblastoma multiforme recurrence

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

Medicare disability recipient dies of brain tumor after having coverage interrupted

Scientists discover new signaling pathway to reduce tumour growth in glioblastoma multiforme

New multidisciplinary approach to glioblastoma multiforme treatment offers extended survival rates

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

EpiCept second-quarter net loss decreases to $4.9 million

Bradmer second-quarter net loss decreases to US$161,000

Scientists discover single-chain protein to destroy GBM cancer cells

NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM

Particles of iron oxide enhance tumor visibility through MRI

New York Times article highlights potential value of early cancer detection technology

Glioblastomas patients with affected stem cell niche experience progression-free survival

Reducing calorie intake can restrict growth, spread of brain cancer: Researchers

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma

CytRx updates on progress in clinical development of bafetinib in three oncology indications

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News